SNAPSHOT IN FIGURES

Macroeconomic

INDIA SNAPSHOT

POPULATION: 1.28 BILLION (2ND IN WORLD) GDP (PPP): USD 9.447 TRILLION (2017)
MEDIAN AGE: 27.9 YEARS (139TH OLDEST IN WORLD) GDP PER CAPITA (PPP): USD 7,200 (2017)
POPULATION GROWTH RATE: 1.17% (96TH IN WORLD) GDP REAL GROWTH RATE: 6.7% (2017)

HEALTH EXPENDITURE: 4.7% OF GDP (2014) Source: CIA World Factbook

GLOBAL COMPETITIVENESS RANKING OF BRICS COUNTRIES

RUSSIA Source:The Economist Intelligence Unit; World Economic Forum

80
INDIA
70

60

50

40

BRAZIL SOUTH AFRICA

30

20

10 CHINA

0
2012/13 2013/14 2014/15

WAGES IN ASEAN (2014) GDP GROWTH IN INDIA (2012-2017)

TOTAL COST OF (%)

ANNUAL HOURLY LABOR 7.93 7.83
MINIMUM MINIMUM (MINIMUM WAGE
COUNTRY WAGE (USD) WAGE (USD) PLUS WELFARE, USD) 7.18 7.11
6.94 6.67
6.54 6.21
CHINA 2,472 1.19 3,337.20 5.48 5.45

INDIA 689 0.28 740

INDONESIA 1,087 0.52 1,187

MALAYSIA 3,107 1.24 3,534.20

PHILIPPINES 1,515 0.73 1,648.30

THAILAND 3,012 1.21 3,168.60

2012-13 2013-14 2014-15 2015-16 2016-17
VIETNAM 1,296 0.64 1,581.10
GDP (11-12) GVA (11-12)

Source: China Briefing Source: India Central Statistics Office

Healthcare & Life Sciences Review: India

 SNAPSHOT IN FIGURES
Pharma Market

EVOLVING BUSINESS MODELS

EXPORT ORIENTED LICENSING PARTIALLY OR WHOLLY OWNED SUBSIDIARIES
BUSINESS-CRAMS
IN-LICENSING OUT-LICENSING INTO INDIA FROM INDIA

DRL

JOINT VENTURES FRANCHISING

ETI
KLINICAL
Source: PwC

TOP 15 COMPANIES IN INDIA (2017) INDIA’S PHARMACEUTICAL SALES AND

Source: AIOCD Awacs
FORECAST (2013-2021F)
MARKET GROWTH
COMPANY SHARE (%) RATE (%)
IN USD BILLION
INDIAN PHARMA
# MARKET (TOTAL) 100 5.5
9-10%
1 SUN PHARMA 5.5 7.0 CAGR
27
2 CIPLA 4.6 3.2 25
23
3 ZYDUS CADILA 3.9 9.8 19 21
17 18
4 MANKIND 3.6 5.4 16
15
5 LUPIN 3.3 7.9
6 TORRENT 3.2 5.9
7 ALKEM 3.1 3.9
8 ABBOTT 3.1 4.7
9 RANBAXY 3.1 4.1
10 GLAXO 3.0 7.6
11 MACLEODS 2.8 6.1
12 INTAS 2.8 5.9
13 GLENMARK 2.4 9.3 2013 2014 2015 2016E 2017F 2018F 2019F 2020F 2021F
14 ARISTO 2.4 3.5
Source: India Pharmaceutical & Healthcare report - Q2 2017, BMI Research, via
15 PFIZER 2.4 -3.5 ISI Emerging market database, accessed July 2017
 SNAPSHOT IN FIGURES
Pharma Manufacturing

SHARE OF INDIA-PRODUCED MEDICINES ON WHO LIST OF RELATIVE COST OF

500
PREQUALIFIED MEDICAL PRODUCTS PRODUCTION WITH US
INDIA Source: WHO (FEB 2015) COST AS BASE (%)
400 REST

300 USA

200 100
100

0
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
EUROPE
NUMBER OF US FDA-APPROVED MANUFACTURING PLANTS BY COUNTRY

>100 Source: Pwc; Crisil Research, Bulk drug exports to scale up in the regulated mar-
kets (December 2008) for India; ICICI Securities, Indian Pharma Sector: Sector
85
Update (December 2008) for Italy, China, Spain, Taiwan, Israel and Hungary.

56
INDIA

28 24
10 8 40
5

Source: Frost and Sullivan Report on Indian

Generic Pharmaceuticals Market, BMI,
INDIA ITALY CHINA SPAIN TAIWAN ISRAEL HUNGARY Financial Express, TechSci Research (March
2014)

KEY PROJECTS ANNOUNCED IN PHARMACEUTICAL MANUFACTURING

COMPANY INVESTMENT AMOUNT YEAR PROJECT DETAILS

INR 10 BILLION ESTABLISHED A FACILITY TO MANUFACTURE TABLETS AND CAPSULES NEAR BENGALURU. IT IS ALSO
2016
(USD 148 MILLION) INVESTING INR 5000 MILLION (USD 73 MILLION) TO UPGRADE ITS UNITS IN NASHIK

INR 3 BILLION ANNOUNCED PLANTS TO INVEST IN A NEW VACCINES PLANT IN THE SPECIAL ECONOMIC ZONE
2017
(USD 44 MILLION) (SEZ), GENOME VALLEY, HYDERABAD

INR 3 BILLION THE COMPANY INAUGURATED ANTI-CANCER DRUG FACILITY AT HALOL IN GUJARAT. AROUND 60
2017
(USD 44 MILLION) MILLION TABLETS AND APSULES AND ABOUT 20 MILLION VIALS OF LIQUID INJECTABLE AND
LYOPHILIZED CONCENTRATES ARE EXPECTED TO BE MANUFACTURED IN THIS UNIT

INR 4.8 BILLION RECEIVED ENVIRONMENTAL CLEARANCE TO INCREASE THE PRODUCTION CAPACITY OF APIS AND API
2017
(APPROX. USD 67 INTERMEDIATES
MILLION) Source: OPPI Industry Analysis, 2017
 SNAPSHOT IN FIGURES
Healthcare

NUMBER OF DOCTORS PER 1,000 PEOPLE (2016) INDIA HEALTHCARE

FACILITIES
2.0

1.6 DOCTORS
1.2
60 PER 100,000
PEOPLE
0.8

0.4 NURSES
0.0
80 PER 100,000
PEOPLE

INDIA PAKISTAN BANGLADESH NEPAL BHUTAN AFGHANISTAN SRI LANKA MALDIVES

PHARMACIES
+ 367,000 (URBAN)
Source: World Health Organization
183,000 (RURAL)

HOSPITAL BED DENSITY

HOSPITALS
BEDS PER 1,000 POPULATION. INCLUDE INPATIENT BEDS AVALIABLE IN PUBLIC, PRIVATE, 30,000 (67% PUBLIC,
GENERAL AND SPECIALIZED HOSPITALS AND REHABILITATION CENTERS
23% PRIVATE)
9.66 Source: Siemens Healthiners
8.17 HOSPITAL BEDS
1.7 MILLION (LESS THAN
ONE PER 1,000 PEOPLE)

4.06
3.10 +
HEALTH CENTERS
171,687 (INCLUDING 145,272
2.84 2.40 SUB-CENTRES WITH BASIC
0.90 FACILITIES)

Source: PwC; World Health Organisation (2008)

Modern Pharmaceuticals (December 2008);
Health System in India: Opportunities and
Challenges for Improvement (July 2005)
Expresspharmaonline.com (2007); and
RUSSIA GERMANY CHINA USA SOUTH AFRICA BRAZIL INDIA World Health Organisation (2007).

INDIA’S CHANGING THERAPEUTIC NEEDS

24% 14% 18% 9% 17% 8%

11% 6% 11%
5% 5%
12% 10% 9% 10%
8% 9%
3% 10% 4% 5%
20% 21%
13%
15% 13%
2001-02 9% 2006-07 2011-12

OTHERS CARDIOVASCULAR ANTI-INFECTIVES GASTROINTESTINAL PAIN/ANALGESICS,

GYNAECLOGICAL &
ANTIDIABETIC NEURO/CNS VITAMINS/MINERALS RESPIRATORY DERMATOLOGY
Source:PwC; ORGIMS Data, Crisil Research, Pharmaceuticals: Review Indian formulation market (2008)